Transcenta to Present I/IIa Study Results of First-line Osemitamab (TST001) plus Nivolumab and CAPOX for Advanced G/GEJ Cancer at ASCO 2024

Transcenta to Present Osemitamab (TST001) and TST003 Study Results at AACR 2024

Transcenta 2023 R&D Day

Transcenta's CEO, Dr. Xueming Qian will be participating in Turning Science Into Business Submit: Cancer research opportunities and advances.

Transcenta to Present Three Study Results at ESMO 2023

Transcenta to Present Efficacy Data by CLDN18.2 Expression Level from Phase 1/2 Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at 2023 ESMO GI Annual Congress